PT - JOURNAL ARTICLE AU - Dolton, Garry AU - Rius, Cristina AU - Hasan, Md Samiul AU - Wall, Aaron AU - Szomolay, Barbara AU - Behiry, Enas AU - Whalley, Thomas AU - Southgate, Joel AU - Fuller, Anna AU - , AU - Morin, Théo AU - Topley, Katie AU - Tan, Li Rong AU - Goulder, Philip J. R. AU - Spiller, Owen B. AU - Rizkallah, Pierre J. AU - Jones, Lucy C. AU - Connor, Thomas R. AU - Sewell, Andrew K. TI - Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope AID - 10.1101/2021.06.21.21259010 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.21.21259010 4099 - http://medrxiv.org/content/early/2021/07/14/2021.06.21.21259010.short 4100 - http://medrxiv.org/content/early/2021/07/14/2021.06.21.21259010.full AB - The adaptive immune system protects against infection via selection of specific antigen receptors on B-cells and T-cells. We studied the prevalent CD8 ‘killer’ T-cell response mounted against SARS-CoV-2 Spike269-277 epitope YLQPRTFLL via the most frequent Human Leukocyte Antigen (HLA) class I worldwide, HLA A*02. The widespread Spike P272L mutation has arisen in at least 14 different SARS-CoV-2 lineages to date, including in lineages identified as variants of concern. P272L was common in the B.1.177 lineage associated with establishing the ‘second wave’ in Europe. The large CD8 T-cell response seen across a cohort of HLA A*02+ convalescent patients, comprising of over 120 different TCRs, failed to respond to the P272L. Sizable populations (0.01%-0.2%) of total CD8 T-cells from individuals vaccinated against SARS-CoV-2 stained with HLA A*02-YLQPRTFLL multimers but failed to bind to the P272L reagent. Viral escape at prevalent T-cell epitopes restricted by high frequency HLA may be particularly problematic when vaccine immunity is focussed on a single protein such as SARS-CoV-2 Spike and provides a strong argument for inclusion of multiple viral proteins in next generation vaccines and highlights the urgent need for monitoring T-cell escape in new SARS-CoV-2 variants.New in Version 2Updated as P272L now seen in 14 different SARS-CoV-2 lineages including the B.1.1.7/Alpha (UK variant) lineageAtomic structures of HLA A*02-YLQPRTFLL and HLA A*02-YLQLRTFLL addedPierre Rizkallah added as an author and author list changed to reflect the contributions of Aaron Wall and Anna Fuller to the newly added datasetsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo payment was received for this work. This work was generously funded by Continuum Life Sciences (CLS) to aid the global COVID-19 effort. CLS provided salary for GD and CR. AKS is a Wellcome Investigator (220295/Z/20/Z) and we acknowledge salary support from Wellcome. EB received support from a Wellcome Trust Institutional Strategic Support Fund Fellowship. MSH was part funded by Enara Bio. We are grateful of funding from the Welsh Government through their Senior Research Leaders Scheme to AKS. LCJ is a Clinical Investigator at Cwm Taf Morgannwg University Health Board (CTMUHB). CTMUHB sponsored and supported the research and provided salary support for LCJ. TRC acknowledges support from the MRC, which funded the computational resources used by the project (grant reference MR/L015080/1), as well as specific funding from Welsh Government, which provided funds for the sequencing and analysis of Welsh samples used in this study, via Genomics Partnership Wales. UK sequencing has been supported by the COVID-19 Genomics UK Consortium (COG-UK), as well as using genomics data that has partly been funded/generated as part of COG-UK. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. JAS is funded by the MRC (MR/T030062/1) and TW is funded by the Wellcome Trust (215800/Z/19/Z). The authors gratefully acknowledge the contributors to GISAID whose sequence data enabled an examination of the global spread of P272L (full list of sequences used and acknowledgements in supplementary information) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participant samples were pseudo-anonymised and the clinical Chief Investigator, Dr Lucy C Jones, was the only individual with access to the confidential record linking sample numbers to identifying information. Pseudo-anonymised sample numbers were not known to participants or to anyone outside of the research group. Our CP study was given a favourable opinion by the Health Research Authority (HRA) Research Ethics Committee London (Brighton & Sussex), IRAS (Integrated Research Application System for HRA) 269506 and was also reviewed by Healthcare Research Wales and Cwm Taf Morgannwg University Health board, with research permissions granted. A copy of the approval letter is attached as a supplemental file. We recruited six participants who had received one dose of a SARS-CoV-2 vaccine as part of the National UK vaccination programme, under ethical approval (Central University Research Ethics Committee (CUREC), University of Oxford, Approval Reference: R71346/RE001).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files). Raw data are available from the corresponding authors on reasonable request.